2022
Cigarette Smoking in Response to COVID-19: Examining Co-Morbid Medical Conditions and Risk Perceptions
Fucito LM, Bold KW, Cannon S, Serrantino A, Marrero R, O’Malley S. Cigarette Smoking in Response to COVID-19: Examining Co-Morbid Medical Conditions and Risk Perceptions. International Journal Of Environmental Research And Public Health 2022, 19: 8239. PMID: 35886090, PMCID: PMC9317071, DOI: 10.3390/ijerph19148239.Peer-Reviewed Original ResearchConceptsChronic medical conditionsMedical conditionsCigarette smokingCOVID-19 risk perceptionCOVID-19 riskGreater oddsSmoking changesHigher COVID-19 risk perceptionsCo-morbid medical conditionsCOVID-19Tobacco cessation treatmentCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicPublic health threatCessation treatmentMedical historyWhite raceSmokingSmoking behaviorSample of adultsOngoing COVID-19Younger ageLogistical regressionHealth threatPreventive healthcare
2011
A preliminary investigation of varenicline for heavy drinking smokers
Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley S. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology 2011, 215: 655-663. PMID: 21221531, PMCID: PMC3645986, DOI: 10.1007/s00213-010-2160-9.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersActive medicationPretreatment groupAlcohol cravingHeavy drinkersOpen-label phaseSmoking cessation pharmacotherapyEffects of vareniclineHeavy drinking daysGreater reductionPlacebo leadVarenicline pretreatmentCessation counselingCessation pharmacotherapyAbstinence ratesCigarette smokingVareniclineSmoking changesDrinking daysPotential treatmentSmokingAlcohol dependenceEntire study periodSmokersHeavy drinking